<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig5">
 <label>Figure 5</label>
 <caption>
  <p>Compound #7 potently inhibits multiple HIV genotypes. PBMCs were exposed to the indicated clinical virus isolates and serial concentrations of compound 
   <bold>#7</bold> and 
   <bold>(a)</bold> half maximal (IC
   <sub>50</sub>) and 
   <bold>(b)</bold> 90% (IC
   <sub>90</sub>) HIV-inhibitory concentrations were determined. Clinical isolates represented the following HIV genotypes: HIV-1M
   <sub>MVP899-87</sub>: HIV-type 1, Major group; HIV-1O
   <sub>MVP5180-91</sub>: HIV-type 1, Outlier group; HIV-2
   <sub>MVP10668-93</sub>: HIV-type 2; HIV-1
   <sub>V13-03413B</sub>: HIV-type 1, Major group/B-clade, isolate with multiple drug-resistance mutations
   <sup>
    <xref ref-type="bibr" rid="CR8">8</xref>
   </sup>. Depicted are the means of three independent experiments with biological triplicates (n = 3; m = 3) and standard deviations (SD).
  </p>
 </caption>
 <graphic xlink:href="41598_2020_57843_Fig5_HTML" id="d29e1381" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
